论文部分内容阅读
慢性活动性丙型肝炎伴肝硬化病人常发 展成肝细胞癌。在某些病人中干扰素似乎有效,但是否能防癌还不知道。因此,作者进行了一项前瞻性随机对照试验,以评估α干扰素(IFN-α)在丙型肝炎病毒(HCV)感染的肝硬化病人中预防肝细胞癌的效果。 作者按下列标准选取了90例病人,即治疗前丙氨酸转氨酶(ALT)持续1年以上异常,HBsAg阴性,无嗜酒或自身免疫性肝病等可导致慢性肝病的其他原因,A级代偿性肝硬化(总胆红素<2mg/dL,血清白蛋白>2.8g/dL,凝血酶原时间为1～4秒,无腹水和肝性脑病体征),无严重血小板减少症(<50000/μl),抗人类免疫缺陷症病毒抗体阴
Chronic active hepatitis C patients with liver cirrhosis often develop into hepatocellular carcinoma. Interferon appears to be effective in some patients, but it is not yet known if it can prevent cancer. Therefore, the authors conducted a prospective randomized controlled trial to evaluate the effect of interferon alpha (IFN-α) on preventing hepatocellular carcinoma in patients with hepatitis C virus (HCV) -related cirrhosis. The authors selected 90 patients according to the following criteria, that is, other causes of chronic liver disease, such as ALT abnormalities, HBsAg-negative, non-alcoholic or autoimmune liver diseases before treatment, Cirrhosis of the liver (total bilirubin <2 mg / dL, serum albumin> 2.8 g / dL, prothrombin time 1 to 4 seconds without signs of ascites and hepatic encephalopathy), no severe thrombocytopenia (<50000 / μl), anti-human immunodeficiency virus antibody negative